ODT News

There are no deals set to price in the first week of the new year; however, filing activity will continue from companies targeting 1Q18 IPOs. The IPO market rounded out 2017 at an even 160 IPOs, raising $35.5 billion in total proceeds, nearly double that of 2016. Refer to our 2017 Annual Review for further insights and...read more

Led by the largest biotech IPO since June 2015, six companies raised $827 million this past week. Biotech Denali Therapeutics raised $250 million, making it the largest biotech IPO of year by both deal size and market cap. The week also included pricings from a cancer biotech, a medical diagnostics company, a California bank, a payday lender and a SPAC. No companies priced...read more

Odonate Therapeutics, which is developing an oral chemotherapy drug for breast cancer, raised $150 million by offering 6.3 million shares at $24, the low end of the range of $24 to $27. Odonate Therapeutics plans to list on the Nasdaq under the symbol ODT. Goldman Sachs, Jefferies and Cowen & Company acted as lead managers on the deal....read more

The 2017 IPO market's final two-week sprint kicks off this week with six IPOs targeting $731 million. The week's three health care IPOs each have significant insider buying, one of which could be the year's largest biotech IPO by market cap, Denali Therapeutics. It and Odonate Therapeutics are both underwritten by Goldman Sachs, the investment...read more